Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerThomas Hatschek, Jonas Bergh, Theodoros Foukakis et al.|JAMA Oncology|2021Cited by 58
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Theodoros Foukakis, Hemming Johansson et al.|Clinical Cancer Research|2022Cited by 41
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifenJohan Rosell, John Carstensen, Bo Nordenskjöld et al.|Acta Oncologica|2017Cited by 32
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-upJohan Rosell, John Carstensen, Olle Stål et al.|Breast Cancer Research and Treatment|2013Cited by 30
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?Jonas Bergh, Thomas Hatschek, Anne Andersson et al.|Journal of Clinical Oncology|2019Cited by 21